Meeting
2020 ASCO Virtual Scientific Program
Phase II, open-label, randomized study of first-line zolbetuximab plus gemcitabine and nab-paclitaxel (GN) in Claudin 18.2–positive metastatic pancreatic cancer (mPC).
Authors
Wungki Park
Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY
Wungki Park , Eileen Mary O'Reilly , Junji Furuse , Futoshi Kunieda , Fei Jie , Hedy L. Kindler
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Pancreatic Cancer
Clinical Trial Registration Number
NCT03816163
Citation
J Clin Oncol 38: 2020 (suppl; abstr TPS4667)
DOI
10.1200/JCO.2020.38.15_suppl.TPS4667
Abstract #
TPS4667
Poster Bd #
275
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Zolbetuximab plus gemcitabine and nab-paclitaxel (GN) in first-line treatment of claudin 18.2–positive metastatic pancreatic cancer (mPC): Phase 2, open-label, randomized study.
First Author: Wungki Park
Poster
2022 ASCO Annual Meeting
Zolbetuximab plus gemcitabine and nab-paclitaxel (GN) in first-line treatment of claudin 18.2-positive metastatic pancreatic cancer (mPC): Phase 2, open-label, randomized study.
First Author: Wungki Park
Poster
2023 ASCO Annual Meeting
FOOTPATH: A randomized, open-label phase-2 study of liposomal irinotecan + 5-FU and folinic acid (NAPOLI) versus sequential NAPOLI and mFOLFOX6 versus gemcitabine/nab-paclitaxel in treatment-naïve metastatic pancreatic cancer (mPDAC).
First Author: Benedikt Westphalen
Poster
2016 Gastrointestinal Cancers Symposium
A randomized, open-label phase II study of nanoliposomal irinotecan (nal-IRI)-containing regimens versus nab-paclitaxel plus gemcitabine in patients with previously untreated metastatic pancreatic adenocarcinoma (mPAC).
First Author: Andrew Dean